# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

## CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 11, 2022

# AMCI Acquisition Corp. II

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of incorporation)

**001-40282** (Commission File Number)

**86-1763050** (I.R.S. Employer Identification No.)

600 Steamboat Road Greenwich, Connecticut (Address of principal executive offices)

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

**06830** (Zip Code)

(203) 625-9200

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
Securities registered pursuant to Section 12(b) of the Act:					

	Trading	Name of each exchange on which
Title of each class	Symbol(s)	registered
Units, each consisting of one share of Class A common stock and one-half of one	AMCIU	The Nasdaq Stock Market LLC
redeemable warrant		
Class A common stock, par value \$0.0001 per share	AMCI	The Nasdaq Stock Market LLC
Redeemable warrants, each warrant exercisable for one share of Class A	AMCIW	The Nasdaq Stock Market LLC
common stock, each at an exercise price of \$11.50		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⊠

X

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

### Item 7.01. Regulation FD Disclosure.

As previously announced, AMCI Acquisition Corp. II, a Delaware corporation ("<u>AMCI</u>"), entered into a Business Combination Agreement (the "<u>Business Combination Agreement</u>") with LanzaTech NZ, Inc. ("<u>LanzaTech</u>").

Furnished as Exhibit 99.1 hereto is an updated investor presentation dated October 11, 2022, to be used by LanzaTech and AMCI in meetings with certain of their stockholders and other persons in connection with the proposed transactions contemplated by the Business Combination Agreement.

The information in this Item 7.01, including Exhibit 99.1, is furnished herewith and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such filing.

### Important Information About the Business Combination and Where to Find It

The proposed business combination will be submitted to stockholders of AMCI for their consideration. AMCI has filed the registration statement on Form S-4 (the "Registration Statement") relating to the business combination, which includes both a preliminary prospectus with respect to the combined company's securities to be issued in connection with the business combination and a proxy statement to be distributed to AMCI's stockholders in connection with AMCI's solicitation of proxies for the vote by its stockholders in connection with the business combination and other matters as described in the Registration Statement. AMCI urges its investors, stockholders and other interested persons to read the preliminary proxy statement/prospectus and, when available, any amendments thereto and the definitive proxy statement/prospectus, as well as other documents filed by AMCI with the SEC, because these documents will contain important information about AMCI, LanzaTech and the business combination. After the Registration Statement is declared effective, AMCI will mail the definitive proxy statement/prospectus to its stockholders as of a record date to be established for voting on the proposed business combination. Stockholders will also be able to obtain a copy of the Registration Statement, including the preliminary proxy statement/prospectus and, once available, the definitive proxy statement/prospectus, as well as other documents filed with the SEC regarding the business combination and other documents filed by AMCI with the SEC, without charge, at the SEC's website located at www.sec.gov or by directing a request to: AMCI Acquisition Corp. II, 600 Steamboat Road, Greenwich, CT 06830.

### Participants in the Solicitation

AMCI and LanzaTech and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the proposed business combination described in this Current Report on Form 8-K (this "Current Report") under the rules of the SEC. Information about the directors and executive officers of AMCI is set forth in the Registration Statement (and will be included in the definitive proxy statement/prospectus). Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of AMCI stockholders in connection with the proposed business combination is set forth in the Registration Statement (and will be included in the definitive proxy statement/prospectus). Stockholders, potential investors and other interested persons should read the proxy statement/prospectus carefully before making any voting or investment decisions. These documents can be obtained free of charge from the sources indicated above.

### Forward-Looking Statements

This Current Report includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of AMCI and LanzaTech. These statements are based on the beliefs and assumptions of the management of AMCI and LanzaTech. Although AMCI and LanzaTech believe that their respective plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, neither AMCI nor LanzaTech can assure you that either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes," "estimates," "expects," "projects," "forecasts," "may," "will," "should," "seeks," "plans," "scheduled," "anticipates," "intends" or similar expressions. The forward-looking statements are based on projections prepared by, and are the responsibility of, AMCI's or LanzaTech's management. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors that may affect actual results or outcomes include, among others, factors relating to the proposed business combination, including the parties' ability to meet the closing conditions of the proposed business combination; the uncertainty of the projected financial information with respect to LanzaTech; the level of AMCI stockholder redemptions, if any; the ability to realize the benefits expected from the business combination; and the ability to list and maintain such listing of the combined company's securities following the business combination; factors relating to the business, operations and financial performance of LanzaTech, including with respect to LanzaTech's development activities, industry partnerships and intellectual property rights; and other factors, such as market opportunities for the combined company, AMCI's or the combined company's ability to raise additional financing in connection with the proposed business combination or otherwise in the future, and the impacts of COVID-19 on the combined company's business; and those factors discussed under the heading "Risk Factors" in the Registration Statement and other documents of AMCI filed, or to be filed, with the SEC. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can AMCI or LanzaTech assess the impact of all such risk factors on the businesses of AMCI and LanzaTech prior to the business combination, and the combined company following the business combination, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to AMCI or LanzaTech or persons acting on their behalf are expressly qualified in their entirety by the foregoing cautionary statements. AMCI and LanzaTech prior to the business combination, and the combined company following the business combination, undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

### Non-Solicitation

This Current Report shall not constitute a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities, in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 Exhibit No.
 Description

 99.1
 Investor Presentation, dated October 11, 2022.

 104
 Cover Page Interactive Data File (embedded within the Inline XBRL document)

4

## SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## AMCI ACQUISITION CORP. II

By: /s/ Nimesh Patel

Name: Nimesh Patel
Title: Chief Executive Officer

Date: October 11, 2022



# LanzaTech

Transforming Carbon. Making Products.

Where does your carbon come from?

©2022 LanzaTech, Inc. All rights reserved.

## Disclaimer

### The Presentation (Together with Oral Statements Made in Connection Herewith)

This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sel, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions. In which such offer, solicitation or sale would be unlawful. The Presentation has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between LanzaTech X2, inc. ["LanzaTech", or the "Company") and AMCI (he "Proposed Education Corporation II" (AMCT), and for no other purpose. The propose them so of the Transaction effected in the Presentation are solicities, son-himston, and here the presentation are solicities, son-himston, and here the presentation is an other proposed Education Companies of the Proposed Education Companies of the

This Presentation and information contained herein constitutes confidential information and is provided to you on the condition that you agree that you will hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or in part without the prior written consent of AMCI and the Company and is intended for the recipient hereof only. By accepting this Presentation, you adminwledge and agree that all of the information contained herein or disclosed only in connection with this Presentation is confidential, that you will not distribute, disclose and use such information it any purpose ofher than for the purpose of your firm's participation in the potential financing, that you will not distribute, disclose or use such information in any way detrimental to LanzaTech or AMCI, and that you will return to LanzaTech and AMCI, delete or destroy this Presentation upon request.

Presentation upon request.

No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law in no circumstances will AMCI, LanzaTech or any of their respective subsidiaries, security holders, affiliates, representatives, partners, directors, officers employees, advisers, or agents be responsible or lable for any direct, indirect, or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, relative con the information contained within it, or on pinions expressed in this Presentation, including individual market data obtained from their part industry publications and sources as well as them respectant peops as well as them respected for other purposes, were obtained from these sources and cannot assure you of the informations accuracy or completeness. This information is subject to change. Some data are also based on the good faith strategies of LanzaTech and AMCI, which are derived from their respective vewer or internal sources as well as the nodeponents or internal sources as well as the modeponents or internal sources as well as the modeponents or internal sources are well as the company's first commercial scale system built and operating in Crima. In addition, this Presentation does not purpor to be all-inclusives or to contain and of the enformation in this presentation, does not purpor to be all-inclusives or to contain and of the enformation in this presentation cannot and adequacy of the information and should make such other investigations as why deem necessary.

Nothing herens should be constructed as legal, financial tax or other advices. You should consult you own advises concerning any legal, financial, tax or other considerations concerning the opportunity described herein. The general explanations included in this Presentation cannot address, and are not interned to address, your specific investment objectives financial intends. Nothing contained herein shall be deemed

and are not intended to address, your specific investment objectives, fenancial situations of Financial reads. Nothing contrained herein shall be desired a recommendation to any party to enter its only transaction or take any course of action.

In connection with the Proposed Business Combination, AMCI has filed with the Securities and Exchange Commission statement on form 5-4 (the "Begistration Statement") containing a preliminary prospecture and any preliminary prospecture of the registration statement in sociated effective, AMCI will mail a definitive proxy statement/prospecture and other interested persons are used to read the preliminary proxy statement/prospecture and other interested persons are used to read the preliminary proxy statement/prospecture and other proposed Business Combination. When available, the definitive proxy statement/prospecture and other relevant materials for the Proposed Business Combination with the SEC when they become available because they will contain important information about AMCI, LurarTach and the Proposed Business Combination with the SEC when they become available because they will contain important information proposed statement proposed business Combination with the SEC when they become available because they will contain important information proposed business Combination. When available, the definitive proxy statement/prospecture and the Proposed Business Combination of the Proposed B

Forward Looking Statements
Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "Delever," "per statements," "continue," "anticipate," "intend," "expert," "should," "you have "perfect to imple the provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are forward-looking statements and the provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are forward-looking statements are forward-looking statements and the Intended Securities Litigation Reform Act of 1995. Forward-looking statements are subject to the Intended Securities Litigation Reform Act of 1995. Forward-looking statements are subject to the Intended Securities Litigation Reform Act of 1995. Forward-looking statements are subject to the Provised for Intended to the Vision Activate Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to a number of risks and AMOT. These forward-looking statements are subject to a number of risks and an uncertainties, including changes in domestic and foreign business, market, intended, policy and intended to the Vision Activate Provised for Intended to serve as and more districts, including changes in domestic and foreign business, market, intended, policy and the provised for Intended to serve as and and uncertainties to a number of risks and uncertainties, including changes in domestic and foreign business, market, intended, policy and the provised for Intended to serve as and exceeded to the Poposed Transactions or Consummate the Proposed Transactions or consummate the Pr

Additional risks related to Lanza Tech's business include, but are not limited to the Company has not yet deployed its technology at scale in commercial deployments, the long bidding and sales cycle in the industry, the success of the project incorporating the Company's systems, governmental regulation, environmental regulation, environmental regulation, environmental regulation, environmental regulation, most of the Company's sales poeline is not in the form of definitive agreements, the Company's systems, whether in the design, manufacturing or assembly or orderwise, the impact of competing technologies, intellectual greents existed claims; ability to expand operations internationally; ability to attract and retain qualified personnel; ability to continue to source materials and components locally, ability of the Company's systems to provide favorable economic benefits to customers as compared to competing technologies, and the continued demand for renewable energy.



## Disclaimer

### The Presentation (Together with Oral Statements Made in Connection Herewith)

If any of these risks materialize or AMCI's or LazaTech's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Then enay be additional risks that rether AMCI nor LazaTech presently know or that AMCI and LazaZech currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, of material-looking statements reflect AMCI are during a did LazaZech and LazaZech and

This Presentation contains projected financial information with respect to LanzaTech, Such projected financial information and is for illustrative purposes only and should not be relied upon as recessarily being indicative of future results. The assumptions and estimates underlying such financial foreast information are inherently uncertain and as subject to a wride variety as ignificant business, economic, competitive, and other risks and uncertainties that could coasse actual results under inherently uncertainties that could coasse actual results and information. Actual results may differ materially from the results contemplated by the projected financial information. Actual results and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such from the results are from the projected financial information in this Presentation. In this Presentation is not information in this Presentation should not be regarded as a representation by any person that the results reflected in such from the results are from the purpose of the purpose of the presentation. In this Presentation is not the purpose of the purpose.

### Financial Information; Non-GAAP Financial Measures

Financial Information; Non-GAAP Financial Measures
The financial information and data contained in this Presentation is unaudited and does not conform to Regulation S-X or Re

This Presentation contains trademarks, service marks, trade names, and copyrights of AMCI, LanzaTech, and other companies, which are the property of their respective owners. The use or display of third parties 'trademarks, service marks, trade name or products in this Presentation is not intended to, and does not imply, a relationship with AMCI or LanzaTech, or an endorsement or sponsorship by or of AMCI or LanzaTech. Solely for convenience, the trademarks, service marks and trade names referred to in this Presentation may appear with the TMC or May more policy but such references are not intended to includes, it any way, that LanzaTech or AMCI will not assert, to the full set extent permitted under applicable blesnows to the fight of the applicable blesnows to these trademarks, service marks, service mar

Preliminary Financial Information
Lanza Tech reports is financial results in accordance with U.S. generally accepted accounting principles. All projected financial information and metrics in this presentation are preliminary. These estimates are not a comprehensive statement of Lanza Tech's financial position and results of operations. There is no assurance that Lanza Tech will achieve its forecasted results within the relevant period or otherwise. Actual results may differ materially from these estimates as a result of actual year-end results, the completion of normal year-end accounting procedures and adjustments, including the execution of Lanza Tech's internal control over financial results on of events prior to the issuance of its financial issuance of its

AMCI and LanzaTech and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the Proposed Business Combination. Information about the directors and executive officers of AMCI is set forth in the registration statement filed with the SEC (and will be included in the definitive proxy statement/prospectus). Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of AMCI stockholders in connection with the Proposed Eusiness Combination is set forth in the registration statement and will be included in the definitive proxy statement/prospectus). Stockholders, potential investors and other interested persons should read the proxy statement/prospectus carefully before making any voting or investment decisions. These documents can be obtained free of charge from the sources indicated above.

This Presentation shall not constitute a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities, in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospection serving the requirements of the Securities and of 1933, as amended.

# - LanzaTech

# AMCI has Identified LanzaTech as a Market Leader in the CarbonTech Ecosystem

### **Key Company Highlights**

Established CarbonTech company transforming carbon emissions to sustainable materials and sustainable aviation fuel ("SAF")

 Disruptive synthetic biology (synbio) platform integrated with proven engineering and commercialscale operations

Profitable, scalable decarbonization solution for industrial sectors today

- 3 commercial plants operating
- 6 additional plants under construction

Capital-light, recurring revenue licensing model

Rapidly growing demand for CarbonSmart™ chemicals from leading consumer brands and SAF from global

Founding shareholder of LanzaJet, a leading SAF company spun out in 2020 and backed by British Airways, Mitsui, Shell, and Suncor

Blue-chip commercial partners and investors

Exceptional management team with proven execution capability


### Pro Forma Capital Structure<sup>1</sup>

- I anzaTech shareholders to roll over 100% of their equity
- AMCI II (NASDAQ:AMCIU) has ~\$150mm of cash in
- PIPE of ~\$125mm as of March 7, 2022, sourced from existing investors, commercial partners, and new investors
- SAFE Investment of \$50mm as of October 3, 2022 from Brookfield

### **Transaction Value**

- Pre-money enterprise value of ~\$1.7bn
- Attractive valuation versus synthetic biology, sustainable materials / fuels, and decarbonization
- World's first public carbon capture and transformation company ("CCT")

# Presenters Nimesh Patel CEO & Director Brian Beem President & Director



Source: LanzaTech managemen

Business Combination Agreement requires minimum net proceeds of \$250mm to close


- LanzaTech













# Proven Technology at the Nexus of Two Mandated Markets



11)

# Sustainable Aviation Fuels Market Opportunity

"SAFs are the only viable near-term option to decrease emissions in the aviation sector, as they are compatible with current aircraft engines and fueling infrastructure and can power flights with no distance limits" (McKinsey & Company)<sup>1</sup>



<sup>1</sup> McKinsey & Company, Critical insights on the path to a net-zero aviation sector. <sup>2</sup> 2020 and 2025 numbers from the International Air Transport Association. 2030, 2035 and 2040 numbers are assumed as 10%, 20% and 30% of global jet fuel demand, respectively. <sup>3</sup> World Economic Forum, Clean Skies for Tomorrow 2030 Ambition Statement. <sup>4</sup> World Economic Forum, Clean Skies for Tomorrow Insight Report



(12)

# LanzaTech Provides a Profitable Pathway to Solving Heavy Industries' Carbon Problem

Addressing industrial carbon emissions while preserving trillions of dollars of existing infrastructure

~25% global greenhouse gas emissions are from heavy industries¹

Among CCT solutions, LanzaTech is ready now and cost effective


	Profitable to CO <sub>2</sub> Emitter	Ability to Use Existing Infrastructure	Carbon Captured / Avoided	Commercially Available
LanzaTech	111	<b>**</b>	111	111
Purchase Offsets	×	<b>///</b>	×	<b>///</b>
Pay Penalties	×	<b>///</b>	×	<b>**</b>
Sequester	×	<b>*</b>	111	✓
Future Technologies	?	?	<b>///</b>	×

Source: LanzaTech management, <sup>7</sup>Climate Watch, The World Resource Institute, Global Change Data Lab; data as of 2016



13

# Global Fortune 500 Partners Deploying LanzaTech's Technology



LanzaTech

(14)

# LanzaTech's Network of Trusted Investors and Partners Range from Industrial Emitters to Aviation Companies and Consumer Brands

Over \$500M Raised from World Class Investors

khosla ventures



























"We have worked with LanzaTech for several years, know their leadership team well and understand the potential of their technology and the role it can play in not only helping us to decarbonize, but also in producing valuable products from our carbon bearing gases which can help the decarbonization of other sectors. Extending our relationship through this investment was therefore a natural next step and we are very pleased to now have an excellent CCU technology company within our XCarb" innovation fund portfolio."

Pinakin Chaubal, ArcelorMittal

ArcelorMittal

Chief Technology Officer

"The integration of LanzaTech's gas fermentation technology into BASF's Verbund enables us to take an important step towards a carbon-neutral circular economy."

Dr. Detlef Kratz, BASF President R&D at BASF

□-BASF

"The LanzaTech process is important because this fuel takes waste,

carbon-rich gases from industrial factories and gives them a second life – so that new fossil fuels don't have to be taken out of the ground. This flight is a huge step forward in making this new technology a mainstream reality."

Sir Richard Branson, Virgin Atlantic

Founder of Virgin Group, following the first commercial flight using SAF from steel mill emissions

"We are capturing emissions before they pollute our atmosphere and are at the same time moving away from fossil-based materials."

Caspar Coppetti, On


Co-Founder and Executive Co-Chairman



ource: Bloomberg, company filing

LanzaTech

(15




# LanzaTech Leadership


## Who We Are Our DNA Jennifer Holmgren Freya Burton Chief Sustainability Officer CEO & Director Process Integration & Julie Zarraga EVP, Engineering Sean Simpson CSO, Co-Founder, & Director Johanna Haggstrom VP, Chemicals & HydrocarbonTech Refining, Aviation & Biotech **Geoff Trukenbrod** CFO Mark Burton General Counsel **Rob Conrado** VP, Engineering Design and Development 150+ years Management Experience Jimmy Samartzis CEO, LanzaJet Steven Stanley Chief Commercial Officer

LanzaTech

(17)




# Broad Technology Platform with Patent Protection Forms Competitive Moat




LanzaTech has over 1,220 patents granted worldwide with over 565 pending

LanzaTech

(19)




# LanzaJet: The Leading SAF Platform




LanzaTech

(21)

# Carbon Emissions to Sustainable Aviation Fuels



# Direct Conversion of CO<sub>2</sub>



# SAF Competitive Landscape

**SAF Key Competitors** 









LanzaTech



Significant competitive advantages from joint process

Lowest Cost Process<sup>1</sup>

Direct CO<sub>2</sub> Feedstock Use

High Potential Jet Yield (90%)<sup>2</sup>


Abundant Lowcost Feedstocks

Non-food Based

Multiple Global Plants in Development

As compared to Gasification + Fischer-Tropsch and hydro-processed esters and fatty acids (HEFA) 2 Source: LanzaTech Management

# Synthetic Biology: LanzaTech's Toolkit to Redefine the Chemicals Industry





LanzaTech

# Leading Synbio Company Transforming Waste to Products

## LanzaTech's Differentiated Platform Allows it to Use Multiple Non-Food Feedstocks

	Product Identification	Microbe Design	Commercial Operations	Feedstock Capability
LanzaTech	✓	✓	✓	
novozymes <sup>-%</sup>	✓	✓	✓	# &
amyris	✓	✓	✓	**
GINKGO BIOWORKS**	✓	✓	<b>√</b> ¹	***

## Why LanzaTech

- Differentiated End-to-End Capability
- Enables Expansion to Sustainable Materials Using Already-Sourced Carbon
- Compatible With Installed Commercial Gas Fermentation Infrastructure
- Successful, At-Scale Piloting of First Key Molecules Complete with Hundreds **Under Development**




















Source: LanzaTech management, Capital IQ, Bloomberg: 1Via their ownership / relationship with Genomatica.

(26)

# LanzaTech SynBio Platform Provides Solutions to Industry Leaders Across Multiple Sectors



# LanzaTech SynBio Platform at the Cutting Edge Across Multiple Capabilities & Processes

### World's First **Anaerobic Biofoundry**

Fully Automated Engineering & Screening of Thousands of Anaerobic Gas Fermentation Strains



### Advanced Al & Modeling

Fully-Integrated Predictive Metabolic & Process Models

### Rapid In Vitro Prototyping Platform **World-Class Partnerships**

Predictive & Low-Cost, Cell-Free Prototyping of Enzymes & Pathway Designs

Partnerships with Leading Synthetic Biology Institutions Across Globe

- LanzaTech

(28)



# LanzaTech CCT Commercial Deployment Status 3 Commercial Plants Operating, 6 Plants Scheduled to Complete Construction in 2022/2023, and 8 Additional Plants in Engineering

Operating



Construction



Engineering



Feedstocks Represented















**Regions Represented** 









**Partner** Investment

~\$850 million

**Estimated Total** Installed Capacity<sup>1</sup>


~700,000 mtpa (230 million gpy)

**Anticipated Carbon** Captured Annually<sup>1</sup>


~1,000,000 tonnes



# Global Impact



### Current Engagements Represent ~\$7.5bn Revenue Opportunity<sup>1</sup>



Source: LanzaTech Management
Note: Based on all active projects in the pipeline advancing through each project development stage. Lifetime revenue
includes all one-time and recurring revenue based on a 20-year useful project life. Some projects in construction are pilot or
smaller capacity opportunities. ¹ Revenue opportunity represents lifetime revenue from a customer.



(32)

### Brookfield Partnership to Drive CCT Scale-Up and Catalyze Project Deployment within LanzaTech Co-Development Strategy

Accelerant to Licensing Business

- Brookfield Framework Agreement unlocks sophisticated infrastructure capital to invest in projects and further validates the LanzaTech technology platform
- Capital-light solution providing much-needed supply for the massive, immediate, and rapidly growing demand from CarbonSmart™ and SAF customers

### 1,500k MT

(~500 million gallons) Potential supply for SAF and CarbonSmart™ materials from these projects1

### 5,000k MT

(~1.8 billion gallons)

Massive Demand Opportunity from LanzaJet alone by 2030

In select identified opportunities, LanzaTech plans to deploy capital directly into projects (~\$85mm total, representing ~5% of total capital required for those projects)

## LanzaTech Co-Development Strategy +\$500mm

Equity commitment to invest in CCT projects meeting preagreed milestones; LanzaTech participates in project upside

#### **Drives Revenue**

LanzaTech receives its one-time and recurring project-related revenu

### **Brookfield**

**Brookfield Partnership Revolutionizes** 

#### **Broad Scope**

Global focus enables broad deployment of CCT technology

#### 50% Offtake

LanzaTech eligible to take up to 50% of the offtake

LanzaTech

### Key Investment Highlights

#### Clear track record

of successfully deploying patented carbon capture and transformation (CCT) technology driving revenue growth in a massive global TAM supported by macro tailwinds

#### **CCT** market leader

built on the foundation of a world class synthetic biology platform delivering value at each stage of technology deployment, and providing significant recurring revenues

### Capital-light, licensing model

generating attractive returns

### Profitable plant-level economics

expected to drive technology deployment and accelerate growth


...........

Attractive entry valuation enabling opportunity to invest in a first of a kind CarbonTech company decarbonizing heavy industry, aviation, and consumer supply chains

### LanzaTech will be the first carbon capture and transformation company to go public

enabling industrial companies to make money from emissions and consumer brands to decarbonize supply chains








### **Business Model**

Integrated and Complementary Business Model

#### Joint Development & Contract Research

- Leverages LanzaTech's synthetic biology, AI, and machine learning expertise to develop new products
- Expands addressable product markets and drives demand for CCT facilities
- Facilitates LanzaTech's continued investment in disruptive synthetic biology platform



#### Licensing of CCT Technology

- Combination of one-time and recurring revenues to deploy LanzaTech carbon capture and transformation (CCT) plants
  - One-time revenues equipment, engineering and startup services
  - Recurring revenues royalties, microbes and media sales, and software licensing

#### CarbonSmart<sup>™</sup> Marketing

- Offtake from CCT plants to supply brands with sustainable products
- Upgrade products with conversion partners into a huge variety of drop in polymers, materials, and fuels

Source: LanzaTech management


37

LanzaTech

### LanzaTech Unit Level Economics

(\$ in millions)

- One-Time Revenue / EBITDA
   Recurring Revenue / EBITDA
- Each carbon capture and transformation plant generates a combination of both one-time and recurring cash flows to LanzaTech
  - One-Time Cash Flows: Engineering Services, Startup Services, and Equipment Sales
  - Recurring Cash Flows: Royalties from Licensing, Microbes & Media, Monitoring & Software, and CarbonSmart™ related marketing fees



Source: LanzaTech management. Plant economics vary by region, size, feedstock, etc. The above is intended to be exemplary of the unit economics of plants that are currently being engineered or constructed



(38)

### **Customer Unit Level Economics**

- Plant economics vary by region, feedstock, and chosen product
- Economics are expected to be attractive for plant sponsor, exclusive of the benefit of carbon emission reductions
- Further upside to plant economics from:
  - Feedstock costs represent up to 40% of cost structure; as cost of carbon increases, this is expected to decrease substantially
  - Price of carbon abated is excluded
  - Direct production of higher value chemicals

LanzaTech's 1st customer is building its 4th plant

Expected Carbon Transformation Plant Economics						
Plant Level Data						
Production (mtpa / million gpy)	5	0,000 / 16.7 Potential avoided				
Carbon Captured (mtpa)	^	cost of \$10mm per annum to the				
Project CapEx (\$mm)		\$150 plant assuming a carbon price of \$100/mt				
	Current (\$/mt)	Carbon Upside (\$/mt)				
Revenues	\$1,115	\$1,115				
Feedstock Costs	\$(250)	+\$100				
OpEx Costs	\$(375)	\$(375)				
Total Cash Costs	\$(625)	\$(275)				
Cash Margin	\$490	\$840				
Gross Cash Margin (\$mm per year)	\$25	\$42				

Source: LanzaTech management. Plant economics vary by region, size, feedstock, etc. The above is intended to be exemplary of the unit economics of plants that are currently being engineered or constructed The Company expects to continue to innovate around its platform technology in order to reduce operating expense and capital expenditures, but those innovations are not reflected in these estimates.



### LanzaTech Projected Financial Profile

(\$ in millions)



Source: LanzaTech management
Note: Adjusted EBITDA adds back stock-based compensation and includes LanzaTech's share of LanzaJet's Net income.
Includes project start revenue, Grants & JDA revenue, dividends and LanzaTech's share of LanzaJet's services revenue. Includes recurring revenue and CarbonSmart revenue Inits projected financial information is preliminary. See "Preliminary
Financial information" above. See also "Non-GAAP Reconciliations" for a reconciliation of these non-GAAP financial measures to their most directly comparable financial measures calculated in accordance with GAAP.

LanzaTech

(40)

### Projected Need to Fund Growth

(\$ in millions)

#### 2022

Investment in carbon capture transformation plant rollout expected to accelerate growth

### 2023 - 2024

Adjusted EBITDA improvement, with positive full-year adjusted EBITDA expected to begin in 2024

#### 2025

Continued strong adjusted EBITDA growth expected to drive significant positive free cash flow generation

#### **2026**


Significant increase in operating and net cash flow as business scales

	Cash Flow Projections						
	2022E	2023E	2024E	2025E	2026E	Total	
	ZUZZE	2023E	Z0Z4E	Z0Z5E	2020E	Total	
Cash Flow from Operations							
CFO (excl. Working Capital)	(\$62)	(\$32)	\$53	\$223	\$404	\$586	
Net ∆ in Working Capital	(15)	(35)	(30)	(74)	(43)	(198)	
Total Cash Flow from Operations	(\$77)	(\$67)	\$23	\$148	\$361	\$388	
Cash Flow from Investing							
Purchases of Property	(\$8)	(\$16)	(\$27)	(\$18)	(\$16)	(\$85)	
Net Investment in Sponsored Projects	1	(7)	(33)	(43)	32	(49)	
Total Cash Flow from Investing	(\$7)	(\$23)	(\$60)	(\$60)	\$16	(\$134)	
Cash Flow from Financing							
Equity Contribution (Net) <sup>1</sup>	\$220	\$0	\$0	\$0	\$0	\$220	
Total Cash Flow from Financing	\$220	\$0	\$0	\$0	\$0	\$220	
Total Δ in Cash	\$136	(\$90)	(\$37)	\$88	\$377	\$473	
Ending Cash Balance	\$264	\$174	\$137	\$226	\$602		

Source: LanzaTech management Omm minimum cash closing condition, and 2022E figure excludes \$30mm attributable to Arcelon/Mittal Safe note investment in December 2021, which will convert (and be part of) PIPE proceeds.








### **Detailed Transaction Overview**

~\$1.7bn Enterprise Value | ~\$125mm PIPE as of March 7, 2022 | \$50mm SAFE Investment as of October 3, 2022



#### Pro Forma Ownership at \$10.00/share



#### **Process Description** \$150 Equity Rollover<sup>3</sup> \$1,817 PIPE Investors<sup>4</sup> Projected Financing<sup>5</sup> Brookfield SAFE Cash to Balance Sheet 125 125 50 Illustrative Fees & Exps.

Total Uses \$2,267

Pre-Money Equity Value	\$1,817
(+) SPAC Shareholders	150
(+) PIPE Shareholders <sup>4</sup>	125
Founders' Shares	38
Projected Financing <sup>5</sup>	125
Post-Money Equity Value	\$2,255
(+) Debt	0
(-) Cash <sup>6</sup>	(521)
Pro Forma Enterprise Value	\$1.734

Pro Forma Capitalization

1,817 **\$2,267** 

Pro Forma Ownership7

Ownership Breakdown	Shares (mm)	%	\$mm
Existing LanzaTech Shareholders	181.7	80.6%	\$1,817
AMCI II Investors	15.0	6.7%	150
PIPE Investors <sup>4</sup>	12.5	5.5%	125
Founders' Shares	3.8	1.7%	38
Projected Financing <sup>5</sup>	12.5	5.5%	125
Equity Ownership	225.5	100.0%	\$2,255

Source: LanzaTech management

\*\*Business Combination Agreement requires minimum net proceeds of \$250mm to close \*\*Excludes interest earned in the trust. SPAC cash amount subject to change depending on the actual interest earned Assumes no redemptions from AMCI stockholders. \*\*Equipment requires minimum net proceeds of \$250mm to close \*\*Excludes interest earned in the trust. SPAC cash amount subject to change depending on the actual interest earned. Assumes no redemptions from AMCI stockholders. \*\*Equipment requires management as pre-money valuation of \$1.7bm plus estimated pre-transaction net cash position of \$85mm, plus \$32mm of aggregate assumed warrant exercise price and aggregate company options exercise price. \*\*Plea Exist of \$-\$1125mms as of March 7, 2022. \*\*Assumes a Projected Financing and excludes impact of gross proceeds from the Brookfield SAFE. \*\*Calculated to reflect net cash position of \$85mm consistent with equity valuation in the Merger Agreement and gross proceeds from the Brookfield SAFE. \*\*Proforms ownership based on \$10.00 per share. Assumes no redemptions from AMCI stockholders. Assumes PIPE size of ~\$125mm. Assumes Projected Financing. Excludes impact of Brookfield SAFE conversion into shares, 3.5mm private warrants, and 7.5mm public warrants.

\*\*LanzaTech\*\*\*

SPAC Cash<sup>2</sup>

Equity Rollover<sup>3</sup> Total Sources

# Identifying the Comparable Universe: LanzaTech is a Global Leader in Sustainable Materials and Fuels

#### **Key Criteria for Defining Best Comps**

- Recognized adjacent industry leaders
- Huge addressable markets
- High-growth financial profile
- Disruptive technologies

#### No perfect public comp available

- Investors will triangulate across various leading Sustainable Materials Peers, Synthetic Biology Companies, and Disruptive Decarbonization Enabling Companies
- Market will focus on predictability of business, longterm growth, margin profile, and defensibility of competitive moat

### Comparable Universe Synthetic Biology GINKGO BIOWORKS novozymes.\*\* amyris LanzaTech PLUG POWER o gevo AKER CARBON CAPTURE • ITM POWER **DESTE** -chargepoin+ **⇔**RIGIN stem Sustainable Materials / Fuels Decarbonization Enablers


### LanzaTech

45)

### Peer Benchmarking

Relative EV / Revenue and EV / EBITDA Valuations

Synthetic Biology
Sustainable Materials / Fuels




LanzaTech

Source: Public disclosures, Capital IQ, Bloomberg and IBES Estimates; market data as of 08-Sep-2022

Note: Assumes Enterprise Value for LanzaTech of \$1,734mm. LanzaTech Adjusted EBITDA adds back stock-based compensation and includes LanzaTech's share of LanzaJet's Net Income. EBITDA measures may not be directly comparable between companies presented.

### Fully Distributed Enterprise Value Sensitivities

(\$ in millions)



Source: LanzaTech management, Bloomberg, Capital IQ, and company disclosures; market data as of 08-Sep-2022.

Note: Midpoint based on LanzaTech peer median. Peer median excludes negatives.



(47)

### Pro Forma Ownership Analysis at Various Trading Prices

(\$ in millions, except per-share data)

Share Price	\$6.00	\$8.00	\$10.00	\$12.00	\$14.00	\$16.00	\$18.00	\$20.00
SPAC Public Shares	15	15	15	15	15	15	15	15
SPAC Public Warrants	-	-	-	0	1	2	3	3
SPAC Founder Shares	4	4	4	4	4	4	4	4
SPAC Founder Warrants	-	-	-	0	1	1	1	1
PIPE Shareholders <sup>1</sup>	13	13	13	13	13	13	13	13
Projected Financing <sup>2</sup>	13	13	13	13	13	13	13	13
Previous Owners and Management Rollover Equity	182	182	182	182	182	182	182	182
Post-Money Equity Value	\$1,353	\$1,804	\$2,255	\$2,711	\$3,184	\$3,657	\$4,130	\$4,603
Implied Returns (\$mm)								
Illustrative IPO Investor 1-Year Retum <sup>3,4</sup>	(40%)	(20%)		23%	53%	83%	113%	143%
Illustrative PIPE Investor 1-Year Return <sup>3</sup>	(40%)	(20%)		20%	40%	60%	80%	100%
SPAC Founder Gain (\$s)	\$19	\$27	\$34	\$43	\$58	\$72	\$87	\$101
Illustrative Founder 1-Year Return	543%	757%	971%	1,236%	1,650%	2,064%	2,479%	2,893%
Implied Ownership	\$6.00	\$8.00	\$10.00	\$12.00	\$14.00	\$16.00	\$18.00	\$20.00
SPAC Public Stockholders	6.7%	6.7%	6.7%	6.8%	7.2%	7.5%	7.7%	7.9%
SPAC Founder	1.7%	1.7%	1.7%	1.7%	1.9%	2.1%	2.2%	2.3%
PIPE Shareholders <sup>1</sup>	5.5%	5.5%	5.5%	5.5%	5,5%	5.5%	5.4%	5.4%
Projected Financing <sup>2</sup>	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.4%	5.4%
Legacy LanzaTech Owners & Mgmt.	80.6%	80.6%	80.6%	80.4%	79.9%	79.5%	79.2%	79.0%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Implied Dilution from Promote & Founder Warrants	1.7%	1.7%	1.7%	1.7%	1.9%	2.1%	2.2%	2.3%

Source: LanzaTech management, AMCl II disclosure

Note: Assumes no redemptions. Warrant dilution calculated using Treasury Stock Method

Assumes PIPE size of ~\$125mm. <sup>2</sup> Assumes a Projected Financing. <sup>3</sup>Assumes investor entry price of \$10/share. <sup>4</sup> Includes public common shares and public warrants.



48)



### **Risk Factors**

Dartain Factors may have a material adverse effect on or business, funcial conditions and results of operations. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unnower of, or that we currently believe are not material, may also become mortaint factors that adversely affect out in that event, you could lose all or part of your investment. All references in this section to "we," our "a "effer both to the business of LanzaTech and its subsidiaries prior to the consummation of the proposed business combination and to the business of the post-business combination guide is combinated and the post-business combination guide is company and its subsidiaries.

The list below has been prepared solely for the purpose of the private placement transaction, and solely for potential private placement investors, and not for any other purpose. Accordingly, the list below is qualified in its entirety by disciousness contained in future documents filed or furnished by LanzaTech and AMCI. Aquisition Corporation II. Inc. ("AMCI") or otherwise with respect to LanzaTech and AMCI. The risks presented in such filings may differ

Our business, results of operations and financial condition have been, and could continue to be, adversely affected by the COVID-19 pandemic

We have incurred losses and anticipate continuing to incur losses.

The success of LanzaTech's plant operations is significantly dependent upon the strong execution and operation of each project by the respective industry partner as we rely, and expect to continue to rely, heavily on industry partners to effect our growth strategy and to execute our business plan. Our failure to successfully maintain and manage these relationships and enter into new relationships could delay our anticipated timelines, prevent the successful development and commercialization of products produced using our process technologies, negatively impact our financial results and perhenting or causationing portfailure.

Even if we are successful in entering into strategic partnering arrangements, there are a number of different arrangements that we can pursue, and there are no assurances that we will select and negotiate the best arrangements for us and our stockholders

We have entered into and anticipate entering into non-binding letters of intent, side letters, memoranda of understanding, term sheets and other arrangements with potential industry partners and cannot assure you that such arrangements will lead to definitive agreements. If we are unable to complete these arrangements in a timely manner and on terms favorable to us, our business will be adversely affected.

We continue to face significant risks associated with our international expansion strategy.

Construction of our or our partners' plants may not be completed in the expected timeframe or in a cost-effective manner. Any delays in the construction of plants could severely impact our business, financial condition, results of operations and prospects.

Failure to continuously reduce operating and capital costs for our and our partners' facilities that deploy our process technologies may impact adoption of our process technologies and could severely impact our business, financial condition, results of operations and prospects.

Maintenance expansion and refurblehment of our and our natures' facilities the construction of new facilities and the development and implementation of our new propose technologies or new generic of our existing propose technologies in unloss similared risks

Our commercial success may be influenced by the price of fossil feedstocks relative to the price of our waste based feedstocks.

Fluctuations in the prices of waste based feedstocks used to manufacture the products produced using our process technologies may affect our or our industry partners' cost structure, gross margin and ability to compete.

Declines in the prices of feedstocks our competitors use to produce their products could allow them to reduce the prices of their products, which could cause us or our industry partners to reduce the prices of the products products products products could allow them to reduce their products, which could cause us or our industry partners to reduce the prices of the products products products products using our process technologies. This could make it uneconomical for our pertners to produce products using our process technologies.

If the availability of the waste based feedstooks used in our process technologies declines or competition for them increases, we or our business partners may experience delayed or reduced production or be required to raise the prices of the products produced using our process technologies, either of which could reduce the demand for the products produced using our process technologies and our revenue.

We compete in an industry characterized by rapidly advancing technologies, intense competition and a complex intellectual property landscape, and our failure to successfully compete with other companies in our industry may have a material adverse effect on our business, financial condition and results of operations and market share.

Technological innovation by others could render our technology and the products produced using our process technologies obsolete or uneconomical.

Our financial results could vary significantly from quarter to quarter and are difficult to predict.

Our financial projections may differ materially from actual results.

We may require substantial additional financing to fund our operations and complete the development and commercialization of the process technologies that produce each of our products or new aspects of our existing process technologies that produce each of our products, and we may not be able to do so an favorable terms.

If we are unable to manage our growth and expand our operations successfully, our reputation and brand may be damaged and our business and results of operations may be harmed.

If we lose key personnel or are unable to attract, integrate and retain additional key personnel, it could harm our research and development efforts, delay the commercialization of the new process technologies or the new aspects of our existing process technologies, delay the launch of process technologies in our development pipeline and impair our ability to meet our business objectives.

LanzaTech



### Risk Factors (Cont.)

No assurances can be given that the Projected Financing will occur or with respect to the actual size, timing and form of any such financing.

Even if we successfully develop process technologies that produce products meeting our industry partners' specifications, the adoption of such process technologies by our industry partners may be delayed or reduced, or our costs may increase, due to customer qualification, negative life cycle assessment, or capital investment procedures.

Failure of LanzaJet to complete its initial facility or failure of third parties to adopt the LanzaJet process in their commercial facilities for the production of sustainable aviation fuel could result in us never owning a majority stake in LanzaJet and may severely impact our business, financial condition, results of operations and prospects.

Lanza-Jet has an exclusive license to some of our intellectual property related to sustainable aviation fuel

Our and our industry partners' failure to accurately forecast demand for any product produced using our process technologies could result in an unexpected shortfall or surplus that could negatively affect our results of operations.

Our success is highly dependent on our ability to maintain and efficiently utilize our technology platform, and to effectively identify potential products for which to develop and commercialize new process technologies, and problems related to our technology platform could harm our business and result in wasted research and development efforts.

We may not be successful in identifying new market apportunities and needs and developing our technology platform, or process technologies to produce products to meet those needs, which would limit our prospects and lead to greater dependency on the success of a smaller number of target products.

Our failure or the failure of our industry partners to realize expected economies of scale could limit our or our partners' ability to sell products produced using our process technologies at competitive prices, negatively impact our ability to enter into other strategic arrangements and the potential for other industry partners to adopt our process technologies, and materially and adversely affect our business and prospects.

Our microbial protein products business, which allows for the extraction of spent microbes that contain protein and other valuable nutrients which can then be used in numerous applications, may not develop as currently expected

Natural or man-made disasters, social, economic and political instability, and other similar events may significantly disrupt our and our industry partners' businesses, and negatively impact our results of operations and financial condition.

Governmental programs designed to incentivize the production and consumption of low-carbon fuels and carbon capture and utilization, may be implemented in a way that does not include products produced using our novel technology platform and process technologies or could be repealed, curtailed or otherwise changed, which would have a material adverse effect on our business, results of operations and financial condition.

Any decline in the value of carbon credits or other incentives associated with products produced using our process technologies could harm our results of operations, cash flow and financial condition.

We expect to rely on a limited number of industry partners for a significant portion of our near-term revenue

We and our industry partners are subject to extensive international, national and subnational laws and regulations, and any changes in relevant laws or regulations, or failure to comply with these laws and regulations could have a material adverse effect on our business and could substantially hinder our and our partners' ability to manufacture and commercialize products produced using our process technologies.

Our success may be dependent on popular, government and corporate sentiment regarding the production of carbon-based fuels and chemicals and the development and deployment of carbon capture and utilization technolog

We and our industry partners use hazardous materials and must comply with applicable environmental, health and safety laws and regulations. Any claims relating to improper handling, storage or disposal of these materials or noncompliance with applicable laws and regulations could be time consuming and costly and could adversely affect our business and results of operations.

We may be subject to product liability claims, which could result in material expense, diversion of management time and attention and damage to our business, reputation and brand.

Ethical, legal and social concerns about genetically engineered products and process technologies that use genetically engineered supplies could limit or prevent the use of products produced using our process technologies and could limit our revenues.

Our genetically engineered microbes may be subject to regulatory scruliny and may face future development and regulatory difficulties. Additionally, failure to obtain import permits for all relevant microbes in jurisdictions with our industry partners could adversely affect our business and results of operations.



### Risk Factors (Cont.)

Our government grants are subject to uncertainty, which could harm our business and results of operations

The requirements of being a public company may strain our resources and divert management's attention, and the increases in legal, accounting and compliance expenses that will result from being a public company may be greater than we anticipate.

Our management has limited experience in operating a public company.

We have identified material weaknesses in our internal control over financial reporting. These material weaknesses could continue to adversely affect the combined company's ability to report its results of operations and financial condition accurately and in a timely manne

If we experience a significant disruption in our information technology systems, including security breaches, or if we fail to implement new systems and software successfully, our business operations and financial condition could be adversely affected.

International sales by us and our industry partners expose us and our industry partners expose us and our industry partners to the risk of fluctuation in currency exchange rates and rates of foreign inflation, which could adversely affect our results of operations.

Changes in interest rates and capital availability may impact investment and financing decisions by our industry partners, which could adversely affect our results of operations.

Any failure by us to manage acquisitions and other significant transactions successfully may have a material adverse effect on our results of operations, financial condition, and cash flows

We believe our company culture has contributed to our success, and if we cannot maintain this culture as we grow and, in particular, become a public company, our business could be harmed

Causes of supply chain challenges, including COVID-19, could result in delays or increased costs for us and our partners deploying our technologies

We and our industry partners have a limited operating history utilizing our technology and different feedstocks, which may make it difficult to evaluate our future viability and predict our future performance.

We have not yet generated material revenues from marketing of CarbonSmart products and sale of equipment and our revenue forecast must be considered in light of the uncertainty and risks frequently encountered by companies in their early stage of development.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Changes in U.S. and foreign tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions

Political and economic uncertainty, including changes in policies of the Chinese government or in relations between China and the United States, may impact our revenue and materially and adversely affect our business, financial condition, and results of operations.

Our operations in China are limited to our joint venture and the license of our process technology to our partners in China. Our ability of our partners to operate in China may be impaired by changes in Chinese laws and regulations, including those relating to taxation, environmental regulation, restrictions on foreign investment, and other matters.

Changes in China's economic, political, or social conditions or legal system or government policies could have a material adverse effect on our business and operations

We may be subject to risks that the Chinese government may intervene or influence our operations at any time

Products produced by our process technologies compete with or are intended to displace comparable products produced using fossil resources. The market prices for these alternatively produced products and commodities are subject to volatility and there is a limited referenceable market for the more sustainable, waste based products that our process technologies enable.

Process performance at LanzaTech's plants is dependent on the quality and quantity of the feedstock supplied from the host facility

The deployment of the technology for alternative waste gas feedstocks can lead to unforeseen issues due to the change in the upstream industrial process

Our patent rights may not provide commercially meaningful protection against competition, and we may be unable to detect infringement of our patents of the patents of th

Differences and uncertainties with respect to legal systems outside the United States could adversely affect the legal protection available to us.

LanzaTech

### Risk Factors (Cont.)

We may not be able to operate our business without infringing the proprietary rights of third parties.

Trade secrets can be difficult to protect and enforce, and our inability to do so could adversely affect our competitive position

If trade secrets are stolen, misappropriated or reverse engineered, others could use these designs to produce competing products

If we are unable to prevent third parties from adopting, registering or using trademarks or otherwise violating our trademark rights, our business could be materially adversely affected.

We may not retain exclusive rights to intellectual property created as a result of our strategic partnering arrangements which could limit our prospects and result in costly and time-consuming disputes.

Some of our intellectual property may be subject to federal regulation such as "march-in" rights, reporting requirements and a preference for U.S. industry, and any such regulations could negatively impact our business and prospects.

We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from developing or selling our process technologies.

Any strategic partnering arrangement that involves the licensing of any of our intellectual property may increase our risks, harm our competitive position and increase our costs.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, or lawsuits asserted by a third party, which could be expensive, time consuming and unsuccessful.

